Alpha Teknova Inc (TKNO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alpha Teknova Inc stock (TKNO) is currently trading at $3.04. Alpha Teknova Inc PS ratio (Price-to-Sales) is 3.94. Analyst consensus price target for TKNO is $9.00. WallStSmart rates TKNO as Sell.
- TKNO PE ratio analysis and historical PE chart
- TKNO PS ratio (Price-to-Sales) history and trend
- TKNO intrinsic value — DCF, Graham Number, EPV models
- TKNO stock price prediction 2025 2026 2027 2028 2029 2030
- TKNO fair value vs current price
- TKNO insider transactions and insider buying
- Is TKNO undervalued or overvalued?
- Alpha Teknova Inc financial analysis — revenue, earnings, cash flow
- TKNO Piotroski F-Score and Altman Z-Score
- TKNO analyst price target and Smart Rating
Alpha Teknova Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Alpha Teknova Inc (TKNO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Alpha Teknova Inc (TKNO) Key Strengths (1)
83.63% of shares held by major funds and institutions
Supporting Valuation Data
Alpha Teknova Inc (TKNO) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Modest revenue growth at 7.80%
Revenue is fairly priced at 3.94x sales
Fairly priced relative to book value
Alpha Teknova Inc (TKNO) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (3.94), Price/Book (2.17) suggest expensive pricing. Growth concerns include Revenue Growth at 7.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -22.80%, Operating Margin at -41.20%, Profit Margin at -42.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -22.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 7.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TKNO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TKNO's Price-to-Sales ratio of 3.94x sits near its historical average of 3.49x (71th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 1% below its historical high of 3.98x set in Mar 2026, and 41% above its historical low of 2.79x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~3.4x, reflecting growing market expectations outpacing revenue growth.
Compare TKNO with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Alpha Teknova Inc (TKNO) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Alpha Teknova Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 41M with 8% growth year-over-year. The company is currently unprofitable, posting a -42.6% profit margin.
Key Findings
Debt-to-equity ratio of 0.22 indicates a conservative balance sheet with 3M in cash.
The company is unprofitable with a -42.6% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -710,000, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Debt management: total debt of 16M is significantly higher than cash (3M). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Alpha Teknova Inc.
Bottom Line
Alpha Teknova Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Alpha Teknova Inc(TKNO)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Alpha Teknova Inc (TKNO) is a leading provider of synthetic biology solutions, specializing in high-quality biological reagents and supplements essential for life sciences research and biomanufacturing. The company addresses critical needs across key sectors, such as vaccine development, cell and gene therapy, and diagnostic testing, while maintaining a steadfast commitment to quality and customer service excellence. With a robust foundation in biotechnology and a focus on innovation, Alpha Teknova is well-positioned to capitalize on the expanding opportunities within the life sciences market, fostering growth and delivering value to its investors.